The U.S. Patent and Trademark Office has issued a patent on compounds discovered at Indiana University Bloomington that could have an effect against the hepatitis B virus.
Hepatitis B (HBV) causes viral hepatitis that can further lead to chronic liver disease and increase the risk of liver cirrhosis and liver cancer. Worldwide, about 2 billion people have been infected with HBV, around 360 million people are chronically infected, and HBV infection causes more than a half-million deaths every year.
The researchers disclosed their innovation to the IU Innovation and Commercialization Office. The mission of the office is to drive innovation to the market for the benefit of the public, the university and innovators for state, national and global commerce. IU personnel can disclose an invention online.